China approves first combination vaccine trial as delta spreads

This study tests the efficacy of a combination of a Chinese Sinovac “inactivated” vaccine and a DNA-based vaccine.

China’s drug regulators have approved the country’s first combination vaccine trial because the rapid spread of Delta variants has raised concerns about the effectiveness of domestic jabs, the company involved in the study said. ..

This test tests the effectiveness of the combination of “inactivation” vaccination It was created by China’s Sinovac using a DNA-based product developed by US pharmaceutical company Inovio, according to a statement released Tuesday.

The statement was issued by Inovio’s China trial partner, Advaccine Biopharmaceuticals Suzhou.

Preclinical studies have shown that “application of two different vaccines provides a stronger and more balanced immune response,” AdVaccine Chairman Wang Bin said in a statement.

There are several types of Covid vaccines, including vaccines that use inactivated or weakened viruses to generate an immune response, and state-of-the-art RNA or DNA-based jabs that use a genetically engineered version of coronavirus. It is included. Genetic code How to make a protein that promotes safety Immune response..

Five of the seven vaccines approved in China are two-shot inactivated vaccines.

Their announced efficacy lags behind RNA jabs by Pfizer-BioNTech and Moderna, with a pre-delta success rate of over 90%.

The World Health Organization has said that there is not yet enough data to say whether it is safe to use two different vaccines together or whether it can boost immunity.

Inovio does not publish its global clinical efficacy data trial.. This is the first DNA-based vaccine tested in China.

China has been fighting the worst coronavirus outbreaks in a few months, and officials say many of the infected have already been vaccinated.

This was added to the call for state-owned Sinopharm and privately-owned Sinovac, two of China’s largest vaccine producers, to provide data demonstrating that their jabs work against the Delta variant. rice field.

Beijing has not yet approved a foreign vaccine for domestic use.

Vaccine dose in China exceeds 1 billion marks

© 2021 AFP

Quote: China acquired August 11, 2021 from for Delta Spread (August 11, 2021) Approved the first combination vaccine trial.

This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.

Source link